Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of dronabinol + acetazolamide for obstructive sleep apnoea
ACTRN12621000809831Phase 2Terminated
- Sponsor
- Incannex Healthcare
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dronabinol and acetazolamide in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Incannex Healthcare. Primary endpoint: Apnoea Hypopnoea Index. Started Aug 2021; status: terminated.
02
Drugs
dronabinolacetazolamide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12621000809831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000809831.